Home / Latest Reports / Human Papillomavirus Vaccine Market

Human Papillomavirus Vaccine Market By Indication, Valence and Distribution Channel - Global Industry Analysis And Forecast To 2027

Published On : June 2022 Pages : 155 Category: Pharmaceuticals Report Code : HC063928

Request Sample Inquiry Before Buying Request for Customization Check Discount

Human Papillomavirus Vaccine Market By Indication (Penile Cancer, Genital Warts, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vulvar Cancer, Vaginal Cancer and Other Indications), Valence (Quadrivalent & Nonavalent and Bivalent) and Distribution Channel (Physician Distributors, Public & Private Alliances, Physicians, Government Entities and Wholesalers) - Global Industry Analysis And Forecast To 2027

Industry Outlook

The HPV represents human papillomavirus. It is the most widely recognized sexually transmitted disease. HPV is normally innocuous and leaves on its own, however a few kinds may prompt genital warts or cancer. There are in excess of 200 kinds of the human papillomavirus disease. Therefore, the Human Papillomavirus Vaccine Market is anticipated to expand and has tremendous scope during the forecast period. The global Human Papillomavirus Vaccine Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

By Indication the market is segmented into Penile Cancer, Genital Warts, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vulvar Cancer, Vaginal Cancer and Other Indications. The Cervical Cancer section is leading the market while the Anal Cancer section is the second leading the market.

By Valence the market is segmented into Quadrivalent & Nonavalent and Bivalent. The Quadrivalent & Nonavalent section is leading the market due to new launch & rise in the number of cases related to cervical cancer.

By Distribution Channel the market is segmented into Physician Distributors, Public & Private Alliances, Physicians, Government Entities and Wholesalers. The Government Entities section is leading the market while the Public & Private Alliances section will show substantial growth.

Regional Insights

The North American region is leading the global Human Papillomavirus Vaccine Market owing to factor like; more number of approvals received by the primary players of the market, increasing number of cases and few other factors.

Human Papillomavirus Vaccine Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Serum Institute of India Pvt. Ltd.
  • Merck & Co. Inc.
  • AstraZeneca
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Sanofi

Some of the key questions answered by the report are:          

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Human Papillomavirus Vaccine Market, By Indication, Estimates and Forecast, 2017-2027 ($Million)

o   Penile Cancer

o   Genital Warts

o   Cervical Cancer

o   Oropharyngeal Cancer

o   Anal Cancer

o   Vulvar Cancer

o   Vaginal Cancer

o   Other Indications

o   Human Papillomavirus Vaccine Market, By Valence, Estimates and Forecast, 2017-2027 ($Million)

o   Quadrivalent & Nonavalent

o   Bivalent

o   Human Papillomavirus Vaccine Market, By Distribution Channel, Estimates and Forecast, 2017-2027 ($Million)

o   Physician Distributors

o   Public & Private Alliances

o   Physicians

o   Government Entities

o   Wholesalers

o   Human Papillomavirus Vaccine Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)

o   Serum Institute of India Pvt. Ltd.

o   Merck & Co. Inc.

o   AstraZeneca

o   GlaxoSmithKline plc.

o   Johnson & Johnson

o   Sanofi

o   Human Papillomavirus Vaccine Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o   North America

§  North America Human Papillomavirus Vaccine Market, By Country

o   U.S. Human Papillomavirus Vaccine Market

o   Canada Human Papillomavirus Vaccine Market

o   Mexico Human Papillomavirus Vaccine Market

o   Europe

§  Europe Human Papillomavirus Vaccine Market, By Country

o   Germany Human Papillomavirus Vaccine Market

o   UK Human Papillomavirus Vaccine Market

o   France Human Papillomavirus Vaccine Market

o   Russia Human Papillomavirus Vaccine Market

o   Italy Human Papillomavirus Vaccine Market

o   Rest of Europe Human Papillomavirus Vaccine Market

o   Asia-Pacific

§  Asia-Pacific Human Papillomavirus Vaccine Market, By Country

o   China Human Papillomavirus Vaccine Market

o   Japan Human Papillomavirus Vaccine Market

o   South Korea  Human Papillomavirus Vaccine Market

o   India Human Papillomavirus Vaccine Market

o   Southeast Asia Human Papillomavirus Vaccine Market

o   Rest of Asia-Pacific Human Papillomavirus Vaccine Market

o   South America

§  South America Human Papillomavirus Vaccine Market, By Country

o   Brazil Human Papillomavirus Vaccine Market

o   Argentina Human Papillomavirus Vaccine Market

o   Columbia Human Papillomavirus Vaccine Market

o   Rest of South America Human Papillomavirus Vaccine Market

o   Middle East and Africa

§  Middle East and Africa Human Papillomavirus Vaccine Market, By Country

o   Saudi Arabia Human Papillomavirus Vaccine Market

o   UAE Human Papillomavirus Vaccine Market

o   Egypt Human Papillomavirus Vaccine Market

o   Nigeria Human Papillomavirus Vaccine Market

o   South Africa Human Papillomavirus Vaccine Market

o   Rest of MEA Human Papillomavirus Vaccine Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Human Papillomavirus Vaccine Market, By Indication

5.1.     Introduction

5.2.     Global Human Papillomavirus Vaccine Revenue and Market Share by Indication (2017-2027)

5.2.1.  Global Human Papillomavirus Vaccine Revenue and Revenue Share by Indication (2017-2027)

5.3.     Penile Cancer

5.3.1.  Global Penile Cancer Revenue and Growth Rate (2017-2027)

5.4.     Genital Warts

5.4.1.  Global Genital Warts Revenue and Growth Rate (2017-2027)

5.5.     Cervical Cancer

5.5.1.  Global Cervical Cancer Revenue and Growth Rate (2017-2027)

5.6.     Oropharyngeal Cancer

5.6.1.  Global Oropharyngeal Cancer Revenue and Growth Rate (2017-2027)

5.7.     Anal Cancer

5.7.1.  Global Anal Cancer Revenue and Growth Rate (2017-2027)

5.8.     Vulvar Cancer

5.8.1.  Global Vulvar Cancer Revenue and Growth Rate (2017-2027)

5.9.     Vaginal Cancer

5.9.1.  Global Vaginal Cancer Revenue and Growth Rate (2017-2027)

5.10. Other Indications

5.10.1.      Global Other Indications Revenue and Growth Rate (2017-2027)

6.       Human Papillomavirus Vaccine Market, By Valence

6.1.     Introduction

6.2.     Global Human Papillomavirus Vaccine Revenue and Market Share by Valence (2017-2027)

6.2.1.  Global Human Papillomavirus Vaccine Revenue and Revenue Share by Valence (2017-2027)

6.3.     Quadrivalent & Nonavalent

6.3.1.  Global Quadrivalent & Nonavalent Revenue and Growth Rate (2017-2027)

6.4.     Bivalent

6.4.1.  Global Bivalent Revenue and Growth Rate (2017-2027)

7.       Human Papillomavirus Vaccine Market, By Distribution Channel

7.1.     Introduction

7.2.     Global Human Papillomavirus Vaccine Revenue and Market Share by Distribution Channel (2017-2027)

7.2.1.  Global Human Papillomavirus Vaccine Revenue and Revenue Share by Distribution Channel (2017-2027)

7.3.     Physician Distributors

7.3.1.  Global Physician Distributors Revenue and Growth Rate (2017-2027)

7.4.     Public & Private Alliances

7.4.1.  Global Public & Private Alliances Revenue and Growth Rate (2017-2027)

7.5.     Physicians

7.5.1.  Global Physicians Revenue and Growth Rate (2017-2027)

7.6.     Government Entities

7.6.1.  Global Government Entities Revenue and Growth Rate (2017-2027)

7.7.     Wholesalers

7.7.1.  Global Wholesalers Revenue and Growth Rate (2017-2027)

8.       Human Papillomavirus Vaccine Market, By Region

8.1.     Introduction

8.2.     Global Human Papillomavirus Vaccine Revenue and Market Share by Regions

8.2.1.  Global Human Papillomavirus Vaccine Revenue by Regions (2017-2027)

8.3.     North America Human Papillomavirus Vaccine by Countries

8.3.1.  North America Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2027)

8.3.2.  North America Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2027)

8.3.3.  United States

8.3.3.1.  United States Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.3.4.  Canada

8.3.4.1.  Canada Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.3.5.  Mexico

8.3.5.1.  Mexico Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.     Europe Human Papillomavirus Vaccine by Countries

8.4.1.  Europe Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2027)

8.4.2.  Europe Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2027)

8.4.3.  Germany

8.4.3.1.  Germany Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.4.  France

8.4.4.1.  France Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.5.  UK

8.4.5.1.  UK Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.6.  Russia

8.4.6.1.  Russia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.7.  Italy

8.4.7.1.  Italy Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.4.8.  Rest of Europe

8.4.8.1.  Rest of Europe Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.     Asia-Pacific Human Papillomavirus Vaccine by Countries

8.5.1.  Asia-Pacific Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2027)

8.5.2.  Asia-Pacific Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2027)

8.5.3.  China

8.5.3.1.  China Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.4.  Japan

8.5.4.1.  Japan Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.5.  Korea

8.5.5.1.  Korea Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.6.  India

8.5.6.1.  India Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.7.  Southeast Asia

8.5.7.1.  Southeast Asia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.5.8.  Rest of Asia-Pacific

8.5.8.1.  Rest of Asia-Pacific Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.     South America Human Papillomavirus Vaccine by Countries

8.6.1.  South America Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2027)

8.6.2.  South America Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2027)

8.6.3.  Brazil

8.6.3.1.  Brazil Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.4.  Argentina

8.6.4.1.  Argentina Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.5.  Columbia

8.6.5.1.  Columbia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.6.6.  Rest of South America

8.6.6.1.  Rest of South America Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.     Middle East and Africa Human Papillomavirus Vaccine by Countries

8.7.1.  Middle East and Africa Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2027)

8.7.2.  Middle East and Africa Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2027)

8.7.3.  Saudi Arabia

8.7.3.1.  Saudi Arabia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.4.  United Arab Emirates

8.7.4.1.  United Arab Emirates Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.5.  Egypt

8.7.5.1.  Egypt Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.6.  Nigeria

8.7.6.1.  Nigeria Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.7.  South Africa

8.7.7.1.  South Africa Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.8.  Turkey

8.7.8.1.  Turkey Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

8.7.9.  Rest of Middle East and Africa

8.7.9.1.  Rest of Middle East and Africa Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

9.       Company Profiles

9.1.     Serum Institute of India Pvt. Ltd.

9.1.1.  Business Overview

9.1.2.   Service Portfolio

9.1.3.  Strategic Developments

9.1.4.  Financial Overview

9.2.     Merck & Co. Inc.

9.2.1.  Business Overview

9.2.2.   Service Portfolio

9.2.3.  Strategic Developments

9.2.4.  Financial Overview

9.3.     AstraZeneca

9.3.1.  Business Overview

9.3.2.   Service Portfolio

9.3.3.  Strategic Developments

9.3.4.  Financial Overview

9.4.     GlaxoSmithKline plc.

9.4.1.  Business Overview

9.4.2.   Service Portfolio

9.4.3.  Strategic Developments

9.4.4.  Financial Overview

9.5.     Johnson & Johnson

9.5.1.  Business Overview

9.5.2.   Service Portfolio

9.5.3.  Strategic Developments

9.5.4.  Financial Overview

9.6.     Sanofi

9.6.1.  Business Overview

9.6.2.   Service Portfolio

9.6.3.  Strategic Developments

9.6.4.  Financial Overview

10.    Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.1. Global Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2027)

10.2. Human Papillomavirus Vaccine Market Forecast by Regions (2017-2027)

10.2.1.      North America Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.1.1. United States Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.1.2. Canada Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.1.3. Mexico Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.      Europe Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.1. Germany Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.2. France Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.3. UK Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.4. Russia Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.5. Italy Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.2.6. Rest of Europe Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.      Asia-Pacific Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.1. China Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.2. Japan Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.3. Korea Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.4. India Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.5. Southeast Asia Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.3.6. Rest of Asia-Pacific Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.4.      South America Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.4.1. Brazil Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.4.2. Argentina Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.4.3. Columbia Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.4.4. Rest of South America Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.      Middle East and Africa Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.1. Saudi Arabia Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.2. United Arab Emirates Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.3. Egypt Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.4. Nigeria Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.5. South Africa Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.6. Turkey Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.2.5.7. Rest of Middle East and Africa Human Papillomavirus Vaccine Market Forecast (2017-2027)

10.3. Human Papillomavirus Vaccine Market Forecast by Indication (2017-2027)

10.3.1.      Human Papillomavirus Vaccine Forecast by Indication (2017-2027)

10.3.2.      Human Papillomavirus Vaccine Market Share Forecast by Indication (2017-2027)

10.4. Human Papillomavirus Vaccine Market Forecast by Valence (2017-2027)

10.4.1.      Human Papillomavirus Vaccine Forecast by Valence (2017-2027)

10.4.2.      Human Papillomavirus Vaccine Market Share Forecast by Valence (2017-2027)

10.5. Human Papillomavirus Vaccine Market Forecast by Distribution Channel (2017-2027)

10.5.1.      Human Papillomavirus Vaccine Forecast by Distribution Channel (2017-2027)

10.5.2.      Human Papillomavirus Vaccine Market Share Forecast by Distribution Channel (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Human Papillomavirus Vaccine Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Human Papillomavirus Vaccine Revenue and Revenue Share by Indication (2017-2018)
Figure Global Penile Cancer Revenue and Growth Rate (2017-2018)
Figure Global Genital Warts Revenue and Growth Rate (2017-2018)
Figure Global Cervical Cancer Revenue and Growth Rate (2017-2018)
Figure Global Oropharyngeal Cancer Revenue and Growth Rate (2017-2018)
Figure Global Anal Cancer Revenue and Growth Rate (2017-2018)
Figure Global Vulvar Cancer Revenue and Growth Rate (2017-2018)
Figure Global Vaginal Cancer Revenue and Growth Rate (2017-2018)
Figure Global Other Indications Revenue and Growth Rate (2017-2018)
Table Global Human Papillomavirus Vaccine Revenue and Revenue Share by Valence (2017-2018)
Figure Global Quadrivalent & Nonavalent Revenue and Growth Rate (2017-2018)
Figure Global Bivalent Revenue and Growth Rate (2017-2018)
Table Global Human Papillomavirus Vaccine Revenue and Revenue Share by Distribution Channel (2017-2018)
Figure Global Physician Distributors Revenue and Growth Rate (2017-2018)
Figure Global Public & Private Alliances Revenue and Growth Rate (2017-2018)
Figure Global Physicians Revenue and Growth Rate (2017-2018)
Figure Global Government Entities Revenue and Growth Rate (2017-2018)
Figure Global Wholesalers Revenue and Growth Rate (2017-2018)
Table Global Human Papillomavirus Vaccine Revenue by Regions (2017-2018)
Figure North America Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure North America Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2018)
Figure North America Human Papillomavirus Vaccine by Countries (2017-2018)
Figure North America Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2018)
Figure United States Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure United States Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Canada Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Mexico Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Europe Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2018)
Figure Europe Human Papillomavirus Vaccine by Countries (2017-2018)
Figure Europe Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2018)
Figure Germany Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Germany Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure France Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure UK Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Russia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Italy Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Rest of Europe Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Asia-Pacific Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Human Papillomavirus Vaccine by Countries (2017-2018)
Figure Asia-Pacific Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2018)
Figure China Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure China Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Japan Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Korea Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure India Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Southeast Asia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure South America Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2018)
Figure South America Human Papillomavirus Vaccine by Countries (2017-2018)
Figure South America Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Brazil Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Argentina Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Columbia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Rest of South America Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Middle East and Africa Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Human Papillomavirus Vaccine by Countries (2017-2018)
Figure Middle East and Africa Human Papillomavirus Vaccine Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Saudi Arabia Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure United Arab Emirates Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Egypt Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Nigeria Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure South Africa Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Turkey Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Human Papillomavirus Vaccine Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2017-2018)
Table Serum Institute of India Pvt. Ltd. Human Papillomavirus Vaccine Financial Overview
Table Merck & Co. Inc. Human Papillomavirus Vaccine Financial Overview
Table AstraZeneca Human Papillomavirus Vaccine Financial Overview
Table GlaxoSmithKline plc. Human Papillomavirus Vaccine Financial Overview
Table Johnson & Johnson Human Papillomavirus Vaccine Financial Overview
Table Sanofi Human Papillomavirus Vaccine Financial Overview
Figure Global Human Papillomavirus Vaccine Revenue (Millions USD) and Growth Rate (2018-2025)
Table Human Papillomavirus Vaccine Market Forecast by Regions (2018-2025)
Figure North America Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure United States Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Canada Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Mexico Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Europe Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Germany Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure France Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure UK Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Russia Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Italy Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Rest of Europe Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Asia-Pacific Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure China Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Japan Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Korea Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure India Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Southeast Asia Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure South America Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Brazil Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Argentina Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Columbia Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Rest of South America Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Middle East and Africa Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Saudi Arabia Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure United Arab Emirates Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Egypt Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Nigeria Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure South Africa Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Turkey Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Human Papillomavirus Vaccine Market Forecast (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Indication (2018-2025)
Figure Global Human Papillomavirus Vaccine Market Share Forecast by Indication (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Indication (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Valence (2018-2025)
Figure Global Human Papillomavirus Vaccine Market Share Forecast by Valence (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Valence (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Distribution Channel (2018-2025)
Figure Global Human Papillomavirus Vaccine Market Share Forecast by Distribution Channel (2018-2025)
Figure Global Human Papillomavirus Vaccine Forecast by Distribution Channel (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*